急性骨髓性白血病市場:KOL的洞察

本報告研究了全球急性髓系白血病市場，提供了市場概況，以及商業推出的療法、管道趨勢和未來前景。

目錄

摘要整理

急性骨髓性白血病的治療流程

調查目的

BCL-2抑制劑

• 已通過核准藥物
  • venkurekusuta/venkurisuto(Venetoclax;AbbVie/Roche)

FLT3抑制劑

• 已通過核准藥物
  • Rydapt(midosutaurin;Novartis)，Xospata(Gilteritinib;Astellas Pharma)，及Vanflyta(kizaruchinibu;Daiichi Sankyo)
• 開發平台藥物
  • kurenoranibu(AROG Pharmaceuticals/Pfizer)

IDH1/2抑制劑

• 已通過核准藥物
  • Tivovo（ivosidenib; 施維雅）、伊迪法（Enasidenib; 施維雅/百時美施貴寶）和Leslichia（Altersidenib; Rigel Pharmaceuticals/Forma Therapeutics）

新處方的化療及低甲基化劑

• 已通過核准藥物
  • Vyxeos(注射用道諾霉素+ Cytarabine微脂體;Jazz Pharmaceuticals)
  • onuregu(CC-486/口服Azacitidine;Bristol Myers Squibb)
  • Inqovi/Inaqovi(ASTX727，Astex Pharmaceuticals/Otsuka Pharmaceuticals)

hedgehog抑制劑

• 已通過核准藥物
  • Daurismo(gurasudejibu，Pfizer)

抗體藥物複合體及放射性免疫複合體

• 已通過核准藥物
  • Mylotarg(Gemtuzumab Ozogamicin;Pfizer)
• 開發平台藥物
  • Iomab-B（131I Apamistamab，Actinium Pharmaceuticals）
  • Actimab-A（林妥珠單抗-AC225; Actinium Pharmaceuticals（鋃化製藥）

其他的作用機制

• 開發平台藥物
  • Uproleseran （GlycoMimetics）
  • Garimpepimut-S（塞拉斯生命科學）
  • Revmenib（Syndax Pharmaceuticals）和Difutomenib（Kura Oncology）

AML治療的未來趨勢與機會

附錄

How might the treatment paradigm change for AML? Why do KOLs say Roche/AbbVie's Venclexta/Venclyxto and azacitidine will remain the standard of care for newly diagnosed AML patients ineligible for intensive chemotherapy? Why do experts believe Novartis' Rydapt could come under pressure from Astellas Pharma's Xospata? KOLs are eagerly anticipating trial results for Syndax Pharmaceuticals' revumenib - why? KOLs critically assess the prospects of launched and pipeline therapies.

Key questions answered:

• What factors do US KOLs say are limiting uptake of Daiichi Sankyo's FLT3 inhibitor Vanflyta?
• Why do experts see a limited role for AROG Pharmaceuticals/Pfizer's FLT3 inhibitor crenolanib?
• Why would most KOLs use Rigel Pharmaceuticals/Forma Therapeutics' Rezlidhia over Servier's Tibsovo in R/R IDH1 mutated AML?
• What Phase III trial data do KOLs say could see Jazz Pharmaceuticals' Vyxeos become the standard chemotherapy backbone?
• What practical challenges do experts identify for Actinium Pharmaceuticals' Iomab-B and Actimab-A pipeline therapies?
• What underpins KOLs' opinions that menin inhibitors could have a practice-changing impact?

Key brands covered in this report:

Table of Contents

Executive summary (10)

Treatment algorithm for acute myeloid leukaemia

Research objectives (10)

BCL-2 inhibitors (18)

• Approved drugs (18)
  • Venclexta/Venclyxto (venetoclax; AbbVie/Roche) (18)

FLT3 inhibitors (23)

• Approved drugs (17)
  • Rydapt (midostaurin; Novartis), Xospata (gilteritinib; Astellas Pharma) and Vanflyta (quizartinib; Daiichi Sankyo) (17)
• Pipeline drugs (6)
  • Crenolanib (AROG Pharmaceuticals/Pfizer) (6)

IDH1/2 Inhibitors (19)

• Approved drugs (19)
  • Tibsovo (ivosidenib; Servier), Idhifa (enasidenib; Servier/Bristol Myers Squibb) and Rezlidhia (olutasidenib; Rigel Pharmaceuticals/Forma Therapeutics) (19)

Novel formulation chemotherapies and hypomethylating agents (24)

• Approved drugs (24)
  • Vyxeos (daunorubicin + cytarabine liposome for injection; Jazz Pharmaceuticals) (11)
  • Onureg (CC-486/oral azacitidine; Bristol Myers Squibb) (5)
  • Inqovi/Inaqovi (ASTX727; Astex Pharmaceuticals/Otsuka Pharmaceuticals) (8)

Hedgehog inhibitors (4)

• Approved drugs (4)
  • Daurismo (glasdegib; Pfizer) (4)

Antibody-drug conjugates and radioimmunoconjugates (15)

• Approved drugs (4)
  • Mylotarg (gemtuzumab ozogamicin; Pfizer) (4)
• Pipeline drugs (11)
  • Iomab-B (131I apamistamab; Actinium Pharmaceuticals) (6)
  • Actimab-A (lintuzumab-Ac225; Actinium Pharmaceuticals) (5)

Other mechanisms of action (21)

• Pipeline drugs (21)
  • Uproleselan (GlycoMimetics) (6)
  • Galinpepimut-S (SELLAS Life Sciences) (6)
  • Revumenib (Syndax Pharmaceuticals) and ziftomenib (Kura Oncology) (9)

Future trends and opportunities in AML treatment (4)

Appendix (4)

• KOL details (4)
  • KOLs from the US (2)
  • KOLs from Europe (1)